HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Draws The Line On Wrinkle Reduction Claims In Warning Letter

This article was originally published in The Rose Sheet

Executive Summary

Wrinkle reduction claims for University Medical Products' Face Lift Collagen 5 products reflect changes to the structure or function of the body, necessitating new drug approval for the products, FDA states in a 1warning letter recently posted to its Web site

Related Content

Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says
CFSAN Cosmetics Oversight Aided By NTP, CDER Collaboration
NAD Takes Initiative In Reviews Of Anti-Aging, Cellulite Claims In 2004
AHA, BHA Products Are Cosmetics Based On Legal Precedent – CTFA
CTFA To Seek Clarity On Wrinkle Product Regulatory Status, BSE Rule
Neutrogena Should Tailor Anti-Cellulite Ad Ingredient Claims – NAD
Avon Cellu-Sculpt 60% Cellulite Reduction Claim Discontinued On NAD Review
Are Wrinkle Treatments With AHAs, BHAs OTCs? FDA Issues Call For Data
AHA Labeling, CFSAN/CDER MoU Among CFSAN’s Completed Cosmetic Goals
AHA Labeling, CFSAN/CDER MoU Among CFSAN’s Completed Cosmetic Goals



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts